10/06/2021: Theradiag: report of the extraordinary general meeting on second call of June 10, 2021

  Croissy-Beaubourg, May 31, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specializing in in vitro diagnostics and theranostics, announces that the Extraordinary General Meeting…

Continue Reading 10/06/2021: Theradiag: report of the extraordinary general meeting on second call of June 10, 2021

31/05/2021: Theradiag announces the launch of HUMABDIAG, a large-scale research project targeting the bioproduction of monoclonal antibodies in Tours

Croissy-Beaubourg, May 31, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specializing in in vitro diagnostics and theranostics, announces the launch of HUMABDIAG, a large-scale…

Continue Reading 31/05/2021: Theradiag announces the launch of HUMABDIAG, a large-scale research project targeting the bioproduction of monoclonal antibodies in Tours

10/05/2021: Theradiag announces the adoption of all ordinary resolutions at the Shareholders’ Meeting of May 6, 2021

  The Extraordinary Shareholders’ Meeting will be held on June 10, 2021 on the second call   Croissy-Beaubourg, May 10, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics…

Continue Reading 10/05/2021: Theradiag announces the adoption of all ordinary resolutions at the Shareholders’ Meeting of May 6, 2021